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Abstract 15 
Infections caused by the intracellular bacterium Chlamydia trachomatis are a global health 16 
burden affecting more than 100 million people annually causing damaging long-lasting 17 
infections. In this review, we will present and discu s important aspects of the interaction 18 
between C. trachomatis and monocytes/macrophages. 19 
 20 
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1 Introduction  34 
Chlamydia trachomatis (C. trachomatis) is a small intracellular Gram-negative human 35 
pathogenic bacterium, which comprises a range of ser vars based on variations in the major 36 
outer membrane protein (MOMP). These serovars are gen tically similar, but cause different 37 
pathological manifestations. Serovar A-C cause the blinding eye condition, trachoma; D-K 38 
cause sexually transmitted genital infection, which can lead to pelvic inflammatory disease, 39 
ectopic pregnancy, and infertility. Finally, serovar L1-L3 can spread from the genital tract to 40 
the lymphatic system causing more disseminated infections. 41 
Chlamydiae are obligate intracellular bacteria with a unique biphasic developmental cycle. 42 
Initially, the small (0.3 µm) infectious but metabolic inactive elementary body (EB) infects 43 
the epithelial host cell. Intracellularly, the EB transforms to a larger (1 µm) and metabolic 44 
active reticular body (RB) and the RB starts to replicate. 45 
C. trachomatis serovars preferably infect mucosal epithelium, but can also infect a range of 46 
other cells including fibroblasts and cells of the immune system [1].  47 
Monocytes and macrophages are recruited to the genital tract during experimental genital 48 
Chlamydia infection and the initial engagement between macrophages and C. trachomatis 49 
may determine the overall outcome of the infection [2,3].  Efficient phagocytosis and 50 
intracellular killing can limit ascension of the infection and provide antigenic material for 51 
activating CD4+ T-cells towards a Th1-mediated immune response - the most critical immune 52 
response to eradicate C. trachomatis infections [4]. Different murine infection models have 53 
demonstrated the importance of these mechanisms in controlling Chlamydia infections.[5,6]. 54 
However, if intracellular elimination in macrophages fails, macrophages may be used as 55 
Trojan horses for bacterial dissemination to the lymphatic system with bacterial replication in 56 
the draining lymph nodes. Especially the L-biovars have been linked to intracellular survival 57 
and dissemination [7]. Lastly, monocytes and macrophages also play important roles in the 58 
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immunopathology of C. trachomatis infections by secreting proinflammatory cytokines 59 
causing collateral tissue damage [3]. Thus, understanding the interaction between 60 
macrophages and C. trachomatis is critical to understand how protective immunity develops 61 
and how the immunological response causes pathology. 62 
A proposed role for C. trachomatis-infected monocytes in the pathogenesis of reactive 63 
arthritis prompted a number of studies in the late 1980’s trying to understand the interaction 64 
between monocytes/macrophages and C. trachomatis. Since these initial studies, several 65 
efforts have been made to understand monocyte/macrophage functions in Chlamydia-induced 66 
inflammation and to understand why C. trachomatis infections tend to be chronic.  67 
Clearly, the intracellular fate of C. trachomatis in macrophages is completely distinct from 68 
the normal developmental cycle observed in epithelial cells. Thus, before discussing the 69 
immunobiology of macrophages during chlamydial infection, we will begin with a concise 70 
presentation of current knowledge about the developmental cycle in epithelial cells to set the 71 
scene for discussions.    72 
2 The developmental cycle of C. trachomatis in epithelial cells 73 
The developmental cycle of C. trachomatis in epithelial cells has been studied in decades and 74 
is now rather well characterized. Depending on the serovar, C. trachomatis EBs engage 75 
epithelial cells in the eye or in the genital mucosa where they attach to host cell surface 76 
components namely heparan sulfate proteoglycans. Upon attachment, C. trachomatis induces 77 
its own uptake by secreting pre-formed effector proteins into the host cell cytosol through a 78 
type III secretion system. One of these effectors is translocated actin-recruiting 79 
phosphoprotein (TarP), which is tyrosin phosphorylated by host cell kinases when 80 
translocated [8,9]. TarP is an actin modifying protein inducing rearrangement of the actin 81 
cytoskeleton and uptake of C. trachomatis into a membrane-enclosed vesicle [10]. Each 82 
chlamydial EB is taken up in an independent vesicle, which is transported to the microtubule-83 
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organizing center in the perinuclear area of the cell. This process is facilitated by interaction 84 
with microtubules and the motor protein dynein [11]. At the microtubule organizing center, 85 
the independent Chlamydia-containing vesicles undergo homotypic fusion thereby 86 
establishing a single large membrane enclosed vacuole alled an inclusion [12]. 87 
The stability and unique physiology of this replicat ve niche is established by inserting 88 
translocated secreted inclusion membrane proteins (Inc ) into the inclusion membrane. Inc 89 
proteins face the cytoplasmic site of the inclusion membrane and interact with different 90 
membrane-sorting proteins including numerous Ras-related protein Rab ( ab) GTPases. 91 
These interactions inhibit fusion with destructive vesicular compartments, e.g. lysosomes 92 
while promoting fusion with nutrient-rich compartments such as lipid-rich Golgi-derived 93 
vesicles [13].  94 
During inclusion formation, the infectious EBs differentiate into metabolically active RBs 95 
that start replicating by binary fission or polarized cell division leading to growth of the 96 
inclusion [14]. After 48-72 hours, the end of the developmental cycle is reached when RBs 97 
have transformed back to EBs. Burst of the cell or membrane extrusion liberates infectious 98 
EBs ready for new rounds of infection. Generally, the underlying mechanisms mediating host 99 
cell exit remain poorly described. However, it was recently shown that chlamydial membrane 100 
extrusion is mediated by interaction with inclusion membrane proteins and host Ca2+-channels 101 
reducing myosin motor activity necessary for extrusion formation [15].  102 
3 Macrophage encounter of C. trachomatis 103 
The first encounter between Chlamydia and mononuclear phagocytes takes place in the 104 
genital tract mucosa. The genital mucosa contains tissue-resident macrophages and 105 
monocytes which engage Chlamydia EBs once liberated from lysed epithelial cells after 106 
completion of the developmental cycle [16]. In early infectious stages, epithelial cells secrete 107 
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several chemokines and proinflammatory cytokines leading to local inflammation and 108 
leukocyte recruitment [17,18]. Using mouse models of genital C. trachomatis infection it was 109 
demonstrated that CD11b-positive cells (monocytes/macrophages) infiltrate the mucosa 110 
during infection [2]. This recruitment is likely induced by secretion of chemokines including 111 
CCL2 and macrophage inflammatory protein-1α known to attract monocytes to the site of 112 
infection [19,20]. Thus, both resident macrophages and monocyte-derived macrophages 113 
recruited from the bloodstream engage invading C. trachomatis in the genital mucosa. The 114 
encountered Chlamydia organisms, liberated from the epithelial cells, consist of both EBs and 115 
RBs. Both forms can trigger the inflammatory response and provide antigenic material as 116 
discussed in the following sections. 117 
4 Macrophage sensing of C. trachomatis 118 
At the site of infection, macrophages recognize the bacteria directly through different innate 119 
immune receptors. Abundant evidence shows that C. trachomatis recognition activates 120 
MyD88- and P38/ERK-dependent signaling pathways, suggesting a role for pattern 121 
recognition receptors  (PRRs) in chlamydial sensing [21–23]. 122 
Monocytes and macrophages are equipped with numerous PRRs, which detect a variety of 123 
conserved structural motifs known as pathogen associated molecular patterns (PAMPs). C. 124 
trachomatis contains several PAMPs; the most well-studied being LPS and Heat Shock 125 
Protein (HSP) 60. Furthermore, HSP70, pORF5, lipoproteins, and macrophage infectivity 126 
potentiator (MIP) have been confirmed to activate host macrophages through PRRs 127 
[21,23,24].  128 
Using photo-chemically inactivated C. trachomatis EBs, Bas et al. show a prominent cell 129 
activation of monocytes and macrophages [24]. In addition, macrophages stimulated with 130 
viable or inactivated C. trachomatis display different cytokine profiles [25–27]. Collectively, 131 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
 
 
these observations suggest that both surface and intracellular receptors detect and respond to 132 
chlamydial infection presumably activating different downstream signaling pathways. 133 
Particularly, members of the toll-like receptor (TLR) family and the nucleotide-binding 134 
oligomerization domain (NOD) like receptor family have been implicated in chlamydial 135 
recognition. 136 
The macrophage receptors involved in C. trachomatis recognition and the subsequent 137 
intracellular events are illustrated in Fig. 1.  138 
4.1 Toll-like receptors in C. trachomatis recognition 139 
Like other Gram-negative bacteria C. trachomatis contains LPS in the outer membrane, a 140 
potent ligand for TLR4 and the co-receptor CD14. Therefore, it is rational to expect an 141 
important role of TLR4 in C. trachomatis recognition. Using CD14 and TLR4 transfected cell 142 
lines, early studies did indeed discover a role for these receptors in recognition of chlamydial 143 
LPS [28,29]. In support, Heine et al. showed that preincubating human peripheral blood 144 
mononuclear cells with a CD14-blocking antibody completely abrogated cellular activation 145 
by chlamydial LPS confirming the Chlamydia-sensing role of CD14 [29]. More recent 146 
studies, however, suggest that the contribution of TLR4 in chlamydial recognition by 147 
monocytes may be limited [23,24,30]. Instead, several r ports suggest that C. trachomatis 148 
induced activation of monocytes is TLR2 dependent. These observations originate from 149 
studies using different strategies including cell lines transfected with different TLRs, primary 150 
cells treated with receptor-blocking antibodies, and primary cells from TLR-deficient mice 151 
[21,23,24,30–32]. Collectively, these studies suggest that TLR2 recognizes live C. 152 
trachomatis EBs together with several PAMPs such as LPS, pORF, lipoproteins, and MIP. 153 
Interestingly, Agrawal et al. found that both TLR2 and TLR4 are involved in C. trachomatis 154 
recognition in human cervical monocytes with a time-dependent contribution of each 155 
receptor[16]. Thus, early detection was TLR4-dependent, but switched to TLR2-dependent 156 
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recognition at later time points. In addition, activa on through TLR4, but not TLR2, induced 157 
interleukin(IL)-12 production [16]. These observations outline the necessity of careful 158 
interpretation of studies investigating chlamydial activation of host cell receptors when 159 
considering experimental design. 160 
An interesting study by Nagarajan et al. found thatnei her TLR2 nor TLR4 are involved in C.161 
trachomatis induced interferon (IFN)-β production. Instead they showed the induction of 162 
IFN-β was dependent on endosome acidification and the adaptor molecule MyD88 [26]. The 163 
authors did not identify the involved receptors, but s ggested that the recognition could be 164 
mediated by intracellular TLRs, including TLR7, -8,and -9 [26]. However, using 165 
macrophages from TLR7- and TLR9 KO mice, the same authors demonstrated that these 166 
receptors are dispensable for IFN-β production [32]. Applying macrophages generated from 167 
human induced pluripotent stem cells, Yeung and colleagues demonstrated an important role 168 
for interferon regulatory factor 5 (IRF5) in intracellular survival of C. trachomatis in 169 
macrophages [33]. IRF5 is activated downstream of TLR7 and TLR8, suggesting a possible 170 
role for these receptors in chlamydia recognition by human macrophages.  171 
Lastly, also TLR1 and TLR6 have been shown to participate in chlamydial recognition by 172 
inducing cell activation in response to chlamydial MIP and the lipopeptide PamCSK4 [24]. 173 
Yet, blocking these receptors does not have the sam effect as blocking TLR2. Thus, TLR2 174 
seems to be the predominating TLR used for macrophage recognition of C. trachomatis while 175 
Chlamydia-induced type I interferon response is TLR-independent highlighting the 176 
importance of other PRRs outside the TLR family.  177 
4.2 NOD-like receptors 178 
TLR-deficiency or TLR-blockage does not abrogate cellular activation completely, proposing 179 
a redundancy in TLR-based C. trachomatis recognition. NOD-like receptors are cytosolic 180 
receptors playing an important role in microbial sensing and innate defense. The NOD-like 181 
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receptor family consists of 23 members of which twohave been reported in C. trachomatis 182 
sensing: NOD1 and nucleotide-binding domain, leucine-r ch repeat family, pyrin domain 183 
containing 3 (NLRP3). The involvement of NOD1 in Chlamydia recognition was established 184 
using expression and gene knockdown studies in HeLa c lls [32,34,35]. At present, no direct 185 
evidence for NOD-based recognition in macrophages exists, although NOD contribution has 186 
been confirmed for other intracellular bacteria andmay also be involved in macrophage 187 
recognition of C. trachomatis [36]. Nonetheless, the contribution of NOD1 has been obscure 188 
since these receptors recognize and ligate peptidoglycan fragments from the bacterial cell wall 189 
[37]. Until recently, peptidoglycan has not been directly detected in C. trachomatis, even 190 
though the C. trachomatis genome contains all necessary genes for peptidoglycan assembly 191 
and is sensitive to beta-lactam antibiotics [38]. In 2014, the Maurelli group, however, directly 192 
detected peptidoglycan in C. trachomatis using a novel metabolic cell wall labeling approach 193 
[39] and later confirmed the presence of muropeptids using mass spectrometry [40]. Finally, 194 
it has been demonstrated that NOD2 expression is upreg lated in C. trachomatis-infected 195 
macrophages, suggesting that NOD2 may also participa e n macrophage recognition of C. 196 
trachomatis [41]. 197 
NLRP3 is another NOD-like receptor which senses molecules associated with cell damage 198 
including adenosine triphosphate (ATP) and uric acid [37]. It constitutes the pattern 199 
recognition moiety of a large multiprotein complex known as the inflammasome. PAMP 200 
mediated inflammasome activation leads to caspase-1 activation and subsequently cleavage 201 
and secretion of IL-1β and IL-18. Chlamydial infection of monocytes activa es the 202 
inflammasome in a NLRP3, AIM2 and MyD88-dependent manner [27,42,43]. Whether 203 
NLRP3 directly recognizes chlamydial PAMPs or if the activation results from endogenous 204 
danger-associated molecular patterns (DAMPs) induced by C. trachomatis is not fully 205 
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understood, but a role for reactive oxygen species (ROS) [43] and autocrine cytokine 206 
signaling (please see the section below) [27] have been proposed.  207 
4.3 Cytosolic DNA receptors 208 
Finally, the cytosolic DNA sensors stimulator of interferon genes (STING) and the absent in 209 
melanoma 2 (AIM2) might also participate in C. trachomatis recognition by sensing 210 
chlamydial nucleic acids (Fig. 1). STING detects cytosolic double-stranded DNA and plays 211 
an important role during both bacterial and viral infections. It was previously demonstrated 212 
that STING mediates IFN-β induction in Chlamydia infected HeLa cells and that C.213 
muridarum induced IFN-β production in J774 macrophages was cyclic GMA-AMP synthase 214 
(cGAS)-dependent. cGAS is a cytosolic DNA-sensing ezyme that detects foreign DNA 215 
converting it to cyclic nucleic acids which is recognized by STING [32,44]. Direct STING-216 
mediated recognition of Chlamydia by macrophages was shown recently by Webster and 217 
colleagues [27]. They demonstrated that STING recognizes cyclic di-AMP from metabolic 218 
active C. trachomatis in murine macrophages leading to IFN-β secretion and autocrine IFN-β 219 
dependent inflammasome activation and IL-1β secretion [27]. However, this observation 220 
awaits confirmation in human primary macrophages. Translating this conclusion directly to 221 
human conditions is controversial due to the debatable metabolic state of C. trachomatis in 222 
human primary macrophages. 223 
AIM2 is another cytosolic receptor sensing double-stranded DNA and like NLRP3 involved 224 
in inflammasome activation. A recent study showed thatC. trachomatis-induced 225 
inflammasome activation in murine macrophages was AIM2 dependent implying that AIM2 226 
might detect chlamydial DNA [27,42].  227 
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4.4 Cellular activation and cytokine production 228 
Although the exact mechanisms mediating macrophage recognition of C. trachomatis are not 229 
fully comprehended, macrophage engagement with C. rachomatis elicits a potent cell 230 
activation inducing the expression of several cytokines, chemokines, and growth factors that 231 
are summarized in Table 1. 232 
5 C. trachomatis entry into macrophages 233 
Several C. trachomatis serovars are internalized into both murine and human primary 234 
macrophages and into different cell lines. However, the involved receptors and molecular 235 
mechanisms mediating chlamydial entry into host immune cells have not been determined yet 236 
[1,43,45,46]. The entry mechanisms are supposedly carried out by phagocytosis or by 237 
receptor-mediated endocytosis [46–48] and the involved receptors might be located to lipid 238 
rafts in the plasma membrane [49]. 239 
Comparing chlamydial infection rates in cell types with different surface receptor profiles 240 
could highlight the involvement of receptors and receptor families. Since C. trachomatis 241 
infects many different cell types the receptors involved may be ubiquitously expressed or 242 
involve multiple entry mechanisms working with essentially equal efficiency [1,50,51]. This 243 
theory is supported by the findings by Sun et al. who observed a similar infection rate 244 
between HeLa cells and murine RAW macrophages [52].In contrast, others find that C. 245 
trachomatis entry occurs much less efficiently in monocytes compared to epithelial cells 246 
indicating involvement of cell-specific receptors [53]. However, this study, among others, 247 
evaluated the entry efficiency by enumerating inclusions two days post infection. Thus, the 248 
data presented in this study may not reflect the actual entry efficiency, since inclusion 249 
numbers after two days also depend on bacterial survival and replication.  250 
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Glycosylated chlamydial surface proteins may provide a moiety for host cell attachment and 251 
entry. Kuo et al demonstrated that C. trachomatis entry into macrophages was significantly 252 
reduced in macrophages deficient in the mannose receptor [54]. The chlamydial ligand 253 
attaching to the mannose receptor has not been identif ed, but it has been suggested that 254 
chlamydial MOMP is glycosylated by mannose [55] andmight therefore serve as ligand for 255 
the mannose receptor facilitating chlamydial entry. The mannose receptor is used by 256 
Mycobacterium tuberculosis to enter macrophages and entry through this receptor is 257 
beneficial for intracellular survival [56]. 258 
Another receptor involved in Mycobacterium tuberculosis entry is the complement receptor 259 
CR3 [57]. Complement receptors are also likely involved in chlamydial entry because C. 260 
trachomatis is opsonized by the complement C3 fragment iC3b which is recognized by CR3 261 
expressed on monocytes and macrophages [58,59]. We recently demonstrated that 262 
complement C3 facilitates rapid uptake of C. trachomatis in human monocytes supporting the 263 
role for CR3 in chlamydial uptake, [59].  264 
Lastly, chlamydial recognition and uptake may be dependent on how Chlamydia are liberated 265 
from infected epithelial cells after completing the d velopment cycle. C. trachomatis liberated 266 
by membrane extrusion is engulfed by murine macrophages through an actin-dependent 267 
mechanism involving extrusion membrane phosphatidylserine (PS) [60].). PS is normally 268 
exposed in the membrane of apoptotic cells and is recognized by apoptotic receptors on 269 
phagocytes. However, blocking PS-receptor interaction by annexin V only partially inhibit 270 
macrophage uptake of Chlamydia containing extrusions, indicating involvement of other 271 
receptor-ligand interactions [60].  272 
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6 The intracellular fate of C. trachomatis in macrophages  273 
Studies exploring the intracellular fate of C. trachomatis in macrophages have been carried 274 
out since the 80’s, but despite more than 30 years of research there is still no clear 275 
understanding of the intracellular trafficking and fate of C. trachomatis in macrophages. Early 276 
studies indicated that C. trachomatis can persist in monocytes for more than 7 days [61–63], 277 
while others, more recent studies, show that C. trachomatis is rapidly degraded in 278 
macrophages [52]. One thing is however certain; the intracellular fate of C. trachomatis in 279 
monocytes and macrophages differs drastically from the normal developmental cycle seen in 280 
epithelial cells as demonstrated in Fig. 2. 281 
After macrophage entry C. trachomatis can induce a state of persistency, where the bacterium 282 
is viable and metabolic active, but does not replicate [1,22,63]. This phenomenon has been 283 
demonstrated for several serovars including Ba, D, K, and L2. Although viable and metabolic 284 
active, the different serovars cannot maintain the developmental cycle, except for serovar L2 285 
[22,64,65]. It appears that serovar L2 can maintain i s infectious potency during monocyte 286 
infection, because lysates from L2-infected monocytes induce inclusion formation in HeLa 287 
cells [53,65]. Nonetheless, we recently demonstrated that C. trachomatis L2 were unable to 288 
maintain its infectious and growth potential after 24 hours of incubation within monocytes 289 
[59]. Different infection/incubation protocols are likely to cause these discrepancies. Table II 290 
provides an overview of studies investigating the intracellular fate of C. trachomatis in 291 
monocytes and macrophages as well as the main findings. Collectively, these findings 292 
indicate that monocytes may respond differently to different serovars; that serovar-specific 293 
survival mechanisms exist; that infection protocols may affect the chlamydial outcome and/or 294 
different macrophage cell types respond differently to C. trachomatis infection. 295 
 296 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
 
 
6.1 Macrophage strategies to restrict C. trachomatis growth 297 
Why is the development of C. trachomatis infection successful in epithelial cells but not in 298 
macrophages? Following entry into the epithelial cell, C. trachomatis forms a membrane-299 
bound vacuole; the inclusion, as previously described in section 1. Yet, C. trachomatis fails to 300 
form a mature inclusion in macrophages and this failure is likely due to several mechanisms 301 
involving phagosome-lysosome fusion, autophagy, and nutrient starvation.  302 
6.1.1 Targeting C. trachomatis for lysosomal degradation 303 
Lysosomal degradation of engulfed bacteria is an important mechanism for bacteria 304 
elimination. Usually, a coordinated procedure involving sequential trafficking to vesicles of 305 
increased acidity target endocytosed or phagocytosed bacteria to lysosomes. . Recruitment of 306 
the proton pump vacuolar H+ ATPase (V-ATPase) mediat s the acidification and the 307 
sequential trafficking is coordinated by a set of GTP-binding proteins including the Rab 308 
GTPases. Of these, Rab5 and Rab7 target vesicles for arly endosomes and late endosomes, 309 
respectively [66]. 310 
Several studies propose that C. trachomatis fails to inhibit phagosome-lysosome fusion in 311 
macrophages. Shortly after entry into murine macrophages, chlamydial EBs locate to Rab7-312 
positive compartments, a late endosome marker, and subsequently associate with the 313 
lysosome marker lysosomal-associated membrane protein 1 (Lamp1) [52,67]. Reducing 314 
lysosome acidification by inhibiting V-ATPase supports chlamydial growth in macrophages 315 
and suggests that C. trachomatis EBs are trafficked through the conventional 316 
phagosome/lysosome pathway in macrophages [52,67,68]. This is completely different from 317 
epithelial cells where Rab GTPases, different from Rab5 and Rab7, are recruited and target 318 
the Chlamydia-containing vesicles to non-destructive vesicular compartments.  319 
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6.1.2 Anti-chlamydial defense by autophagy 320 
Autophagy is another means of targeting bacteria to lys somes. Autophagy induction by C. 321 
trachomatis was first described by Pachikara et al. in HeLa cells [69] and accumulating 322 
evidence suggests that autophagy also plays a substantial role in macrophage clearance of C. 323 
trachomatis [52,67]. 324 
Autophagy is a ubiquitous mechanism used to degrade an  sequester cytosolic protein and 325 
organelles to maintain cell homeostasis [70]. During autophagy, a double membrane structure 326 
assembles which surrounds the protein/organelle/pathogen thereby creating a vesicular 327 
structure called an autophagosome. The autophagosome i  directed to lysosomes and after 328 
fusion, the  autophagosomal content is degraded [70]. The autophagic pathway is illustrated in 329 
Fig. 3. 330 
Upon entry into macrophages, C. trachomatis associates with the autophagosomal marker 331 
LC3 and is observed in large doubled membrane structures resembling autophagosomes 332 
[52,68]. In accordance, functional experiments show that autophagic activity is elicited in 333 
infected macrophages, but not in infected epithelial cells [52].Knockdown of autophagy 334 
protein 5 (ATG5), a key regulator of autophagy, increases C. trachomatis progeny numbers in 335 
THP-1 cells [67]. The autophagic potency of macrophages can be enhanced by IFN-γ 336 
stimulation mediated by IFN-inducible proteins called guanylate-binding proteins. During 337 
IFN-γ cell activation, these proteins co-localize with chlamydial EBs and direct them for 338 
lysosomal fusion through an autophagy-dependent pathway [67]. External ATP stimulation 339 
can induce chlamydial vacuole fusion with lysosomes in addition to IFN-γ activation,, but 340 
whether this process occurs through autophagy has not been determined [71]. The entry and 341 
intracellular trafficking of C. trachomatis into macrophages is illustrated in Fig. 3. 342 
 343 
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6.1.3 Direct interaction by perforin-2 344 
Perforin-2 is a phylogenetic conserved pore-forming protein containing a domain, which is 345 
also found in other vital immunological proteins such as complement C9 and perforin-1 [72]. 346 
Varying expression of perforin-2 during C. trachomatis infection may account for the 347 
different infection outcome between macrophages and epithelial cells [73]. Monocytes and 348 
macrophages constitutively express perforin-2, and IFN-γ stimulation induce expression in 349 
epithelial cells. Unfortunately, this induction is inhibited by chlamydial proteins [73]. 350 
Perforin-2 expression increases in macrophages, but not in epithelial cells, during C. 351 
trachomatis infection indicating that perforin-2 expression may be regulated by gene 352 
regulatory factors acting downstream of immune receptors. The local cytokine milieu 353 
generated by C. trachomatis infected epithelial cells increases perforin-2 expr ssion in either 354 
resident macrophages or invading monocytes, potentially boosting perforin-2 expression 355 
before direct contact with the bacterium [74].  356 
Inducing perforin-2 knock down by small interfering RNA in macrophages leads to 357 
maturation of C. trachomatis inclusions and the growth pattern resembles that of epithelial 358 
cells. In addition, chlamydial growth is restricted in perforin-2 expressing epithelial cells. The 359 
anti-chlamydial defense mechanism responsible for these observations is mediated through 360 
direct contact with the bacterium [73]. Thus, macrophages synthesize perforin-2 in response 361 
to C. trachomatis and prevent chlamydial-induced perforin-2 degradation by limiting 362 
chlamydial de novo protein synthesis. This provides an efficient chlamydial killing 363 
mechanism involving direct contact with the bacterium.  364 
 365 
6.1.4 Induction of reactive oxygen and nitrogen species 366 
Production of reactive oxygen species and reactive nitrogen species (ROS and RNS) are 367 
important microbicidal mechanisms against various pathogens [75]. Inducible nitric oxide 368 
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synthase (iNOS) is produced during C. trachomatis infection in macrophages and leads to 369 
nitric oxide production [16,64], which is strongly correlated with chlamydial clearance [76]. 370 
The mechanisms leading to iNOS induction involve a ROS- and cathepsin-dependent 371 
mechanism acting downstream of TLR2 activation [77]. In addition, C. trachomatis, but not 372 
C. pneumoniae, induces ROS production in macrophages. The differential induction of ROS 373 
could explain why C. trachomatis is killed earlier than C. pneumoniae in macrophages [64]. 374 
Indeed, macrophages deficient in NADPH oxidase, a ROS generating enzyme, support 375 
intracellular survival and replication of C. trachomatis [27]. Finally, ROS has also been 376 
implicated in inflammasome activation since adding a  antioxidant to C. trachomatis infected 377 
macrophages reduces caspase-1 activation [43]. 378 
  379 
6.1.5 Limiting access to host cell nutrients 380 
C. trachomatis exploits a parasitic nature relying on host cell components for maintaining 381 
metabolism and survival. Hence, restricting chlamydial access to host cell nutrients inhibits 382 
bacterial growth. 383 
Tryptophan is an essential amino acid required for chlamydial growth and survival. An 384 
essential anti-chlamydial defense mechanism is IFN-γ induced expression of indoleamine 2,3-385 
dioxygenase (IDO). IDO catabolizes tryptophan to L-kynurenine leading to depletion of 386 
cytosolic tryptophan and chlamydial growth restriction [78]. Macrophages induce IDO 387 
expression in response to C. trachomatis infection by different serovars, which may 388 
contribute to the growth restriction observed in macrophages [22,79].  389 
Acquisition of host cell lipids to the inclusion mebrane is regarded an essential step in 390 
chlamydial inclusion maturation and reproduction [80]. This process involves Golgi-391 
disruption and acquisition of lipid-containing Golgi-vesicles. By preventing cleavage of 392 
golgin84, macrophages prevent Golgi-disruption during infection thereby preventing 393 
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inclusion maturation [52]. In epithelial cells however, golgin84 is cleaved leading to Golgi 394 
disruption and acquisition of lipid-rich Golgi-vesicles to the growing inclusion [52]. 395 
Another approach of restricting chlamydial growth by nutrient starvation is by reducing 396 
intracellular iron levels [81]. Increasing intracellular iron levels by reducing surface-397 
expressed ferroportin in macrophages increases the fraction of large C. trachomatis inclusions 398 
[82]. Thus, chlamydial growth is dependent on host-cell iron metabolism. Modulation of these 399 
pathways could provide a defense mechanism against C. trachomatis. Expression of ferritin 400 
heavy chain is increased during C. trachomatis infection of monocytes [79]. Ferritin could be 401 
anti-chlamydial by binding intracellular iron thereby decreasing the concentration of free iron 402 
available for C. trachomatis in the infected cell.   403 
7 Antigen-presentation of C. trachomatis infected macrophages 404 
The primary role for monocytes and macrophages in anti-bacterial immunity is mediated by 405 
phagocytosis and secretion of proinflammatory cytokines. However, monocytes and 406 
especially macrophages contain major histocompatibility complex (MHC) class I and MHC 407 
class II molecules making them competent inducers of adaptive immunity. Possible antigen-408 
presentation pathways in C. trachomatis infected macrophages are illustrated in Fig. 4. 409 
 410 
7.1 Macrophages and CD4+ T-cells in C. trachomatis infection 411 
Th1 responses are the predominant adaptive immunological response to control and eliminate 412 
C. trachomatis infection like most other intracellular bacteria [83]. Activated Th1 cells secrete 413 
IFN-γ and TNF-α, which potentiate microbicidal mechanisms in macrophages and inhibit 414 
chlamydial growth in infected epithelial cells as previously described. 415 
How do monocytes and macrophages contribute to Th1 immunity during chlamydial 416 
infection? Activation of naïve CD4+ T-cells requires T-cell recognition of chlamydial 417 
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antigens presented in MHC class II molecules together with co-receptor ligation and an 418 
appropriate cytokine signal. Several C. trachomatis proteins have been shown to contain 419 
MHC class II epitopes including HSP60, MOMP and PMP [84]. During infection with C. 420 
trachomatis monocytes upregulate the expression of MHC class II molecules and the co-421 
stimulatory receptors CD40, CD80 and CD86 [16,41,74,79]. IFN-γ and IL-12 drive T-cell 422 
polarization in the Th1 direction. Several studies have shown that C. trachomatis leads to 423 
IFN-γ and IL-12 expression and secretion from infected macrophages (Table I) [16,41,85,86]. 424 
Hence, macrophages infected with C. trachomatis seem to direct the adaptive response 425 
towards Th1 immunity.  426 
Although Th1 mediated immunity is pivotal for infection control and resolution, the 427 
macrophage induced T-cell response is not directed solely against Th1 activation. Some 428 
investigations suggest that C. trachomatis infected monocytes might also drive a Th2 429 
mediated response or modulate the effector functions of activated T-cells [87–89]. Lu et al. 430 
showed that murine macrophages pulsed ex vivo with UV-inactivated C. muridarum failed to 431 
induce a Th1 dominant response when adoptively transferred. Instead, mice immunized with 432 
ex vivo pulsed macrophages had high titers of IgG1 Chlamydia-specific antibodies suggesting 433 
an IL-4 mediated Th2 response [88]. The authors did not evaluate whether macrophages in 434 
fact induced IL-4 secretion in response to C. trachomatis pulsing.  In fact, macrophage 435 
secretion of IL-4 have not yet been established, but micro array analysis have shown that IL-4 436 
mRNA is upregulated in human monocytes early after inf ction [90].  437 
7.2 Macrophages and CD8+ T-cells in C. trachomatis infection  438 
Besides the Th1- response, cell-mediated immunity against Chlamydia may also involve 439 
CD8+ T-cells.  When activated, these cells differentiate into cytotoxic T-cells, which possess 440 
efficient killing mechanisms targeted against host cells infected with intracellular pathogens.  441 
The relevance and importance of CD8+ mediated immunity during chlamydial infections has 442 
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not yet been fully established. Different studies have shown that Chlamydia-specific CD8+ T-443 
cells are generated during C. trachomatis infection and that they participate actively in anti-444 
chlamydial immunity [91]. 445 
CD8+ T-cells recognize small peptides loaded on MHC class I molecules. Therefore, 446 
pathogen-derived antigens need to be proteolytically processed before loading onto MHC 447 
class I happens. Enzymatic processing of MHC class I ntigens is mediated by the 448 
ubiquitin/proteasome system located in the cytosol. Thus, only pathogens/antigens accessing 449 
the cytosol are targets for MHC class I antigen presentation and CD8+ T-cell activation. The 450 
process of presenting exogenously acquired antigens on MHC class I is known as antigen 451 
cross-presentation and  this immunological mechanism is restricted to professional antigen-452 
presenting cells, such as dendritic cells and macrophages [92]. Accordingly, C. trachomatis is 453 
only a potential target for antigen cross-presentation if chlamydial antigens enter the cytosol. 454 
In epithelial cells, C. trachomatis secretes different proteins into the host cell cytosol. If these 455 
proteins are secreted in macrophages too, entering MHC class I processing is possible[9,93–456 
95]. However, these proteins are important for inclusion formation and may not be secreted in 457 
macrophages since C. trachomatis fail to induce inclusion maturation in macrophages. 458 
Interestingly though, Prantner et al. demonstrated that the translocon protein sec61 locates to 459 
the chlamydial inclusion in macrophages [32]. Sec61 has recently been demonstrated to 460 
facilitate antigen translocation from an endosomal compartment into the cytosol [96]. Thus, 461 
when C. trachomatis EBs or RBs are degraded in macrophages, chlamydial proteins may 462 
escape the vesicular compartment entering the cytosol and may be tagged for MHC class I 463 
presentation. This process is potentially facilitated by increased expression of MHC class I 464 
and transporter associated with antigen processing (TAP1) in macrophages activated by 465 
conditioned medium from C. trachomatis infected epithelial cells [74]. TAP is a 466 
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transmembrane protein that facilitates transport of antigenic peptides from the cytosol to the 467 
MHC class I loading compartment in the ER.  468 
7.3 Modulation of T-cell responses 469 
Although chlamydial infection initiates both CD4+ and CD8+ cell-mediated immune 470 
responses, eradiction of the infection does not occur. The insufficiency of chlamydial 471 
clearance mechanisms may be due to chlamydial-induced attenuation of T-cell immunity. 472 
Jendro and colleagues demonstrated that culture supernatants from C. trachomatis infected 473 
monocytes induced apoptosis of T-cells by a TNF-α dependent mechanism [97,98]. Another 474 
way of regulating T-cell immunity is by attenuating T-cell effector functions. It has been 475 
demonstrated that chlamydial-infected macrophages reduce IFN-γ release from co-cultured T-476 
cells [99].   477 
8 Summary 478 
Chlamydial growth in monocytes and macrophages is limited and differs drastically from the 479 
classical growth pattern seen in epithelial cells. The restricted growth pattern is mediated by 480 
several mechanisms including lysosome trafficking, perforin-2 interaction, production of 481 
reactive species, and nutrient starvation. The receptors and mechanisms mediating chlamydial 482 
recognition and entry are poorly understood and nee further investigation. Additionally, 483 
there is still dissension on the intracellular trafficking of C. trachomatis in macrophages.  484 
Confirmation of current observations in human primay cells remains. 485 
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Figure legends 813 
 814 
Figure 1. Macrophage receptors involved in recognition of C. trachomatis. TLRs 815 
expressed at the cell surface recognize several chlmydial PAMPs such as LPS, HSP60, 816 
lipoproteins, MIP, pORF5, and probably many others. Ligation of the different TLRs initiate 817 
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a signaling cascade that ultimately leads to nuclear translocation of transcription factors and 818 
expression of genes encoding proinflammatory cytokines. After entry, C. trachomatis is 819 
engaged by another set of receptors in the intracellular compartment. Induction of IFN-β is 820 
dependent on endosomal acidification and MyD88, suggesting that intracellular TLRs may 821 
participate in IFN-β induction. The cytosolic NOD-like receptor NOD1 recognizes 822 
peptidoglycan and ligation leads to activation of IKKs (IκB kinases) and NF-κB. NLRP3, 823 
another NOD-like receptor, recruits the adaptor protein ASC (apoptosis-associated speck-like 824 
protein containing a CARD) and P-Casp1 (pro-caspase 1) during infection forming a 825 
multiprotein complex known as the inflammasome. Inflammasome assembly leads to 826 
caspase-1 activation and caspase-1-dependent cleavage nd secretion of IL-1β. The NLRP3 827 
activating compound has not been identified yet, but several endogenous molecules including 828 
ATP and ROS (reactive oxygen species) can activate NLRP3. Also the DNA-sensing receptor 829 
AIM2 is involved in Chlamydia-induced inflammsome activation. Finally, chlamydial DNA 830 
can be recognized by the ER-associated receptor STING (stimulator of interferon genes). 831 
STING ligation leads to translocation of IRF3 (Interferon Regulatory Factor 3) and 832 
transcription of type I interferons. 833 
 834 
Figure 2. C. trachomatis infection in epithelial cell and monocyte. 835 
Both cell types have been cultured with C. trachomatis L2 for 24 hours. In HeLa cells (left), 836 
C. trachomatis replicate and form a large inclusion at 24 hours, but it fails to do so in 837 
monocytes (right).  838 
 839 
Figure 3. Entry and intracellular trafficking of C. trachomatis in macrophages.  840 
C. trachomatis entry into macrophages is facilitated by both ubiqitous and cell type-specific 841 
surface receptors. The entry mechanisms are supposedly carried out by receptor-mediated 842 
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endocytosis and phagocytosis, involving the mannose rec ptor, complement receptors and 843 
possibly receptors recognizing phosphatidylserine (PS) in Chlamydia-containing extrusions. 844 
Upon entry, C. trachomatis EBs are localized to Rab7-positive compartments indicative of 845 
late endosomes. Rab7 traffics Chlamydia-containing vesicles to lysosomes, where the bacteri  846 
are killed by the acidic pH and lysozymes.  847 
Autophagy is another mechanism that targets C. trachomatis to lysosomes. Here, several 848 
ATG proteins facilitate the formation of a double-mbrane structure that surrounds the 849 
bacteria creating an autophagosome. Interferon-induc ble GBPs (guanylate binding proteins) 850 
modifies the autophagosomal membrane and facilitates fusion with lysosomes creating 851 
autolysosomes that leads to chlamydial killing. Finally, perforin-2 leads to C. trachomatis 852 
growth restriction by targeting EB directly or by modulating the compartment in which the 853 
bacteria reside.  854 
 855 
Figure 4. Antigen-presentation in Chlamydia-infected macrophages. Both CD4+ T-cells 856 
and CD8+ T-cells are activated during C. trachomatis infection. Both MHC class II and the 857 
co-stimulatory molecules CD80/CD86 are upregulated in macrophages during chlamydial 858 
infection. In addition, both IL-12 and IFN-γ are secreted from activated macrophages 859 
directing the CD4+ T-cell differentiation in a Th1 direction. Activated Th1 cells secrete TNF-860 
α and IFN-γ, which potentiate the microbicidal potency of macrophages. In addition, also Th2 861 
immunity is elicited and the Th2-differentiation is mediated by IL-4, which is 862 
transcriptionally upregulated in response to infection.  863 
The mechanisms involved in Chlamydia-induced CD8+ T-cell activation have not been 864 
elucidated, but it may occur through antigen cross-presentation. In this pathway, chlamydial 865 
proteins may escape the endosomal compartment leading to enzymatically processing by the 866 
proteasome. Chlamydia-derived peptides are trafficked to the ER or endosomal structures via 867 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
35 
 
 
 
TAP (Transporter associated with antigen processing) where they are loaded onto MHC class 868 
I molecules.  869 
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Table 1. Cytokines and chemokines induced by Chlamydia in macrophages 
Study Cytokine/chemokine Species Cells Chlamydia 
spp. 
Reference 
Abdul-Sater et al. IL-1β Human THP-1 C. trachomatis L2 [37] 
Agrawal et al. IL-1β, IL-6, IL-12, IFN-γ Human Cervical 
monocytes 
C. trachomatis* [9] 
Bas et al. IL-1β, IL-6, IL-8, TNF-α Human Monocytes C. trachomatis L2 [18] 
Darville et al. IL-6, TNF-α Mouse Peritoneal 
macrophages 
C. muridarum [39] 
Datta et al IL-1β, IL-10, TNF-α Human Monocytes C. trachomatis 
Ba, D, and L2. 
[16] 
Hui et al. IL-1β, IL-8, TNF-α Human THP-1 pORF5 from 
C.trachomatis 
[15] 
Jendro et al. TNF- α Human Monocytes C. trachomatis K [40] 
Kol et al. IL-6 Human Monocytes HSP60 from C. 
trachomatis 
[41] 
Krausse-Opatz et 
al. 
IL-8 Human Monocytes C. trachomatis K [42] 
Lausen et al. IL-6, IL8 Human Monocytes C. trachomatis L2 [43] 
Manor et al. TNF- α Human Monocyte-
derived 
macrophages 
C. trachomatis K 
and L2 
[44] 
Marangoni et al. IFN-γ, TNF- α Human Monocytes C. trachomatis D [45] 
Mpiga et al.  IL-1 β, IL-6, IL-8, IL-12 Human THP-1 (human) C. trachomatis L2 [46] 
Nagajaran et al. IFNa, IFNb, IP10, TNF-α Mouse Peritoneal 
macrophages 
C. trachomatis 
Nigg. 
[20] 
Rothermel et al. IL-1α, IL-1β Human Monocytes C. trachomatis L2 [47] 
Schrader et al IL-1α, IL-1β, IL-3, IL-4, IL-
5, IL-6, IL-9, IL-10, IL-11, 
IL-15, IL-16, IL-17, IL-18, 
IFN-γ, TGF- β1, TGF- β2, 
TNF- α 
Human Monocytes C. trachomatis K [48] 
Yilma et al. IL-6, IL-8, TNF- α Mouse J774 
macrophages 
C. muridarum [19] 
Yilma et al.  IL-1α, IL-1β, IL-6, IL-9, IL-
12, IL-15, GM-CSF, G-CSF, 
CCL2, CXCL1, CXCL5, 
CXCL10. 
Mouse J774 
macrophages 
C. muridarum [35] 
Wang et al. MIP-2 Mouse Monocyte-
derived 
macrophages 
Recombinant 
predicted 
lipoproteins from 
C. trachomatis D. 
[17] 
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Table 2. Intracellular survival of C. trachomatis in monocytes/macrophages 
Study Chlamydia spp. Species Cells Method Results Ref 
Lausen et al. 2018 C. trachomatis L2 Human Peripheral blood 
monocytes 
IFU1 on McCoy cells No IFUs 24h p.i.2 [59] 
Nagarajan et al. 2018 C. muridarum Mouse Peritoneal 
macrophages 
IFU on L929 cells 200% of initial IFUs are recovered 
24h p.i. 
[100] 
Webster et al. 2017 C. trachomatis ?* Mouse BMDM3 Quantification of LPS and 
qPCR on 16S RNA 
LPS can be detected 24h p.i. [27] 
Yeung et al. 2017 C. trachomatis F Human iPSdM4 and 
monocyte-derived 
macrophages 
Quantification of GFP and 
IFU assay on McCoy cells 
Bacteria replicates in iPSdM for 48h 
p.i. 
[33] 
Zuck et al. 2017 C. trachomatis L2 Mouse BMDM IFU assay on HeLa cells No IFUs 4h and 8h p.i. [60] 
Zuck et al. 2016 C. trachomatis B, D, L2 
and C. muridarum 
Mouse BMDM Direct detection by 
fluorescence 
All serovars except serovar B are 
detected 6h p.i.  
[101] 
Finethy et al. 2015 C. muridarum Mouse BMDM qPCR on 16S RNA Survives 24h p.i. [42] 
Rajaram et al. 2015 C. muridarum Mouse RAW264.7 cells IFU assay on McCoy cells Reproductive infection is observed 
24h p.i.and is MOI5 dependent 
[77] 
Datta et al. 2014 C. trachomatis Ba, D 
and L2 
Human Peripheral blood 
monocytes 
IFU assay on HeLa cells Serovar L2, but not Ba and D 
survives for 2 days p.i. 
[53] 
Marangoni et al. 
2014 
C. trachomatis D Human Peripheral blood 
monocytes 
IFU assay on LLC-MK2 cells No detectable IFUs 24h p.i. [64] 
Chen et al. 2013 C. trachomatis G Human Peripheral blood 
monocytes 
IFU assay on Hep-2 cells IFUs are detected 48h p.i. [102] 
Fields et al. 2013 C. trachomatis B, D, L2 
and C. muridarum 
Mouse BV2 macrophages 
+ RAW 264.7 cells 
IFU assay on HeLa cells L2 IFUs are detected 24h p.i [73] 
Sun et al. 2012 C. trachomatis L2 Mouse RAW 264.7 cells IFU assay on HeLa cells IFUs are detected 24h p.i. [52] 
Azenabor et al. 2011 C. trachomatis ?* Human THP-1 cells IFU assay on Hep-2 cells Few detectable IFUs 72h [99] 
Yasir et al. 2011 C. trachomatis L2 and 
C. muridarum 
Mouse RAW 264.7 cells IFU assay on HeLa cells Four times as many IFUs are 
recovered from muridarum compared 
to L2 24h p.i 
[68] 
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Paradkar et al. 2008 C. trachomatis ?* Mouse BMDM Direct inclusion visualization 10% cells contain large inclusions 
24h p.i. 
[82] 
Schnitger et al. 2006 C. trachomatis K Human Peripheral blood 
monocytes 
qPCR on ompA, euo and 
groEL1 
Expression of all genes are observed 
after 7 days in monocytes 
[103] 
Gerard et al. 2002 C. trachomatis K Human Peripheral blood 
monocytes 
qPCR on chlamydial rRNA 
and metabolic enzymes 
Most mRNAs are detected after 2 
days and rRNA after 5 days p.i. 
[104] 
Gerard et al. 1998 C. trachomatis K Human Peripheral blood 
monocytes 
qPCR on chlamydial mRNA Transcripts of glyQs, gseA, hsp60 
and omp2 are observed 10 days p.i. 
[105] 
Nettelnbreker et 
al.1998 
C. trachomatis K Human U937 cells Direct inclusion visualization 
and IFU assay on Hep-2 cells 
Chlamydial replication is observed 
from day 1 to 10 p.i. 
[106] 
Chen et al. 1996 C. trachomatis D Mouse RAW 264.7 cells Direct inclusion visualization 
and IFU assay on McCoy 
cells 
IFU recovery increases from 24h to 
48h and IFUs are recovered 6 days 
p.i. 
[76] 
Koehler et al. 1996 C. trachomatis K Human Peripheral blood 
monocytes 
TEM6 visualization of 
inclusions 
Atypical inclusions are observed for 
up to 10 days p.i. 
[63] 
Numazaki et al. 1995 C. trachomatis L2 Human U937 cells PCR on chlamydial DNA DNA is detected 90 days p.i. [62] 
Schmitz et al. 1993 C. trachomatis K Human Peripheral blood 
monocytes 
IFU assay on Hep-2 cells 3-5% of original inoculum is detected 
after 2h and few inclusions after 24h. 
MOMP is detected up until 14 days 
p.i. 
[61] 
Zhong et al. 1988 C. trachomatis L1 Mouse Peritoneal 
macrophages 
In vivo infection followed by 
IFU assay on HeLa cells 
IFUs are recovered 60h p.i. [107] 
Bard et al. 1987 C. trachomatis L2 Human HL-60 cells Direct inclusion visualization 
and IFU assay on McCoy 
cells 
IFUs are recovered 72h p.i [108] 
Yong et al. 1987 C. trachomatis B, C, I, 
L1 and L2 
Human Peripheral blood 
monocytes 
Direct inclusion visualization 
and IFU assay on HeLa cells 
LGV biovars survive and replicate for 
48h, but only in cells incubated for 8-
9 days. Trachoma biovars do not 
survive. 
[109] 
Bard et al. 1986 C. trachomatis L2 Human Peripheral blood 
monocytes 
Direct inclusion visualization 
and IFU assay on McCoy 
cells 
<0,5% IFU yield compared to initial 
inoculum 32h p.i. 
[110] 
Manor et al. 1986 C. trachomatis L2 Human Peripheral blood 
monocytes and 
monocyte-derived 
macrophages 
TEM visualization of 
inclusions + IFU assay on 
MA-104 cells 
Recovery of IFUs from monocytes at 
all tested time points up until 120h 
p.i. IFUs from macrophages decrease 
at 24h and increase at 72h.  
[111] 
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1IFU: Inclusion forming units; 2p.i.: post inoculation; 3BMDM: Bone marrow-derived macrophages; 4iPSdM: Induced pluripotent stem cell-derived macrophages; 5MOI: Multiplicity of 
infection, 6TEM: Transmission electron microscopy. 
*Serovar not specified 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Macrophages contain typical 
inclusions.  
[Kuo et al. 1978 C. trachomatis B and L2 Mouse Peritoneal 
macrophages 
IFU assay on HeLa cells Both serovars form inclusions at 48h. 
4% of serovar B is recovered after 
48h while 50% of serovar L2 is 
recovered. B is detected for 4 days 
and L2 for 9 days p.i.. 
[112] 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
